WAVE Life Sciences Ltd (WVE) FinancialsWVEFinancialWAVE Life Sciences Ltd

Evaluating the bottom line, Wave Life Sciences Ltd. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -3248.33%, while the net margin is -3052.60%. These profitability ratios, combined with a Return on Equity (ROE) of -68.31%, provide a clear picture of how effectively WVE converts its operational activities into shareholder value.

In the context of the broader market, WVE competes directly with industry leaders such as CADL and GERN. With a market capitalization of $1.07B, it holds a leading position in the sector. When comparing efficiency, WVE's gross margin of 100.00% stands against CADL's N/A and GERN's 94.94%. Such benchmarking helps identify whether Wave Life Sciences Ltd. is trading at a premium or discount relative to its financial performance.

The company reported a Q2 2026 revenue of only $2.3 million, down from $8.7 million in the prior year, indicating a significant decline in income. The net income for Q2 2026 was a loss of $69.4 million, highlighting ongoing financial struggles.